Trevena, Inc.

Equities

TRVN

US89532E2081

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.46 USD +0.31% Intraday chart for Trevena, Inc. -8.22% -36.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Trevena, Inc. Promotion of Barry Shin to the Position of Executive Vice President and Chief Operating Officer CI
Trevena Raises $4 Million via Placement, Warrant Exercise MT
Trevena, Inc. announced that it has received $1.945934 million in funding CI
Trevena to Raise $4 Million From Private Placement, Warrants Exercise Agreements MT
Trevena, Inc. announced that it expects to receive $1.945934 million in funding CI
Trevena Inc. Receives OLINVYK Agreement with Premier, Inc CI
Trevena Files $200 Million Mixed Shelf MT
Trevena, Inc. Announces Acceptance of Abstract Examining the Use of Olinvyk in Patients with Acute Burn Injuries CI
Transcript : Trevena, Inc., Q3 2023 Earnings Call, Nov 14, 2023
Trevena, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (TRVN) TREVENA Posts Q3 Revenue $180,000 MT
North American Morning Briefing : Caution -2- DJ
Trevena, Inc. Announces Board Changes CI
Trevena, Inc. Announces Completion of Initial Analysis of Olinvyk Continuous Respiratory Monitoring Data from Volition Study CI
Trevena, Inc. Announces Retirement of Michael Dougherty as A Member of the Board of Directors and as A Member of the Audit Committee, Effective as of September 14, 2023 CI
Transcript : Trevena, Inc. - Special Call
Top Premarket Gainers MT
Trevena, Inc. Announces Preliminary TRV045 Data from Two Proof-Of-Concept Studies Evaluating S1pr Mechanism of Action and CNS Target Engagement CI
Trevena, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (TRVN) TREVENA Reports Q2 Revenue $3M MT
Trevena, Inc. Appoints Mark Corrigan to Board of Directors CI
Trevena, Inc. Announces New Topline OLINVYK Data Highlighting Reduced Cost Per Admission from Artemis Real-World Outcomes Study CI
Expected House Vote on Debt Ceiling Deal Weighs on Sentiment, Pushing US Equity Futures Lower MT
Trevena Receives $3 Million Milestone Payment From Partner Jiangsu Nhwa Pharmaceutical MT
Top Premarket Gainers MT
Chart Trevena, Inc.
More charts
Trevena Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company's product, OLINVYK (oliceridine) injection, is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. It is also engaged in three differentiated investigational drug candidates: TRV045, TRV250, and TRV734. TRV045 is a novel sphingosine-1-phosphate (S1P), receptor modulator that may offer a new, non-opioid approach to managing chronic pain, as well as treating epilepsy and seizure disorders. TRV250 is a G-protein biased delta-opioid receptor (DOR), agonist as a compound with a mechanism for the treatment of acute migraine. TRV734 is a new chemical entity (NCE) targeting the same mechanism of action at the mu-opioid receptor (MOR). TRV734 is used for the treatment of opioid use disorder.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.46 USD
Average target price
6.5 USD
Spread / Average Target
+1,313.04%
Consensus
  1. Stock
  2. Equities
  3. Stock Trevena, Inc. - Nasdaq
  4. News Trevena, Inc.
  5. Trevena : Enrolls First Patient in Late-Stage Study of Olinvyk Injection in China